Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $103 | $186 | $219 | $259 |
| - Cash | $36 | $67 | $130 | $122 |
| + Debt | $30 | $31 | $0 | $0 |
| Enterprise Value | $97 | $150 | $89 | $137 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$12 |
| % Margin | – | – | – | – |
| EBITDA | -$98 | -$52 | -$43 | -$20 |
| % Margin | – | – | – | – |
| Net Income | -$102 | -$52 | -$43 | -$101 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.71 | -1.08 | -1.06 | -2.63 |
| % Growth | -58.3% | -1.9% | 59.7% | – |
| Operating Cash Flow | -$86 | -$43 | -$35 | -$18 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$86 | -$43 | -$35 | -$18 |